Auxly Business Model Canvas

The Auxly Leamington joint venture at the Sunens greenhouse delivers a 1.2 million‑sq ft automated footprint (operational since 2024) that yields predictable, high‑quality cannabis at per‑gram cash costs ~30–40% below indoor peers, supplying Auxly’s manufacturing lines for oils, vapes, and edibles and preserving vertical integration benefits without Auxly shouldering full capital or operating ownership.

Auxly’s key partners—Imperial Brands (C$70m 2021 investment; C$30–50m annual program support by 2025), provincial wholesalers (access to Canada’s C$5.6B 2024 recreational market), Leamington JV (1.2M sq ft greenhouse; 30–40% lower per‑gram cash cost), ~1,200 retail outlets (~$45M retail sales 2024 est.), and logistics partners (supporting ~4,500 kg/mo shipments)—drive scale, cost and speed.

Auxly builds and maintains brands such as Back Forty and Foray, driving consumer insight research, packaging design, and multi-channel advertising under Canada’s Cannabis Act limits; in 2024 Auxly recorded C$58.7m revenue and invested ~C$3.2m in marketing and brand development to stand out in a commoditized market.

Auxly runs R&D at Dosecann (C$12M, 2024), automated manufacturing (6,000 kg/month, 65% distillate), brand ops (C$3.2M marketing, C$58.7M revenue 2024), QA/compliance (99.2% batch compliance, C$6.4M QA spend), and sales/distribution (120 reps, ~3,500 accounts, >92% on‑shelf 2025).

The Leamington greenhouses supply >80% of Auxly Brands Inc.’s Canada-grown biomass, enabling large-scale output; in 2024 they produced ~15,000 kg wet biomass—enough for ~3.0 million grams of finished product after processing yields.

Facilities use automated climate, irrigation, and harvest systems that cut labor hours ~35% and lower cost per gram by an estimated 20%, giving secure, high-quality raw material access central to product margin stability.

Key resources: Dosecann R&D/manufacturing hub (C$12.4M pipeline 2024), Leamington greenhouses (>80% biomass; ~15,000 kg wet 2024), proprietary formulations/patents (+6 ppt gross margin), raised ≈C$45M (2023–24) + C$30M credit, CA$16.8M revenue FY2024, 7 SKUs launched 2024; focus: disciplined capex, inventory turns, profitability 2025.

Through brands like Back Forty, Auxly offers mass-market cannabis that balances quality and affordability, with 2024 retail ASPs around CAD 8.50 per gram versus premium CAD 12–15, widening reach during economic tightening.

By scaling cultivation and distribution—Auxly reported pro forma 2024 production capacity ~18,000 kg and SG&A efficiencies improving gross margin by ~4 percentage points—competitive pricing preserves experience without margin erosion.

Auxly delivers consistent, tested cannabis and next‑gen formats (vapes, edibles) that drove C$45M branded sales in 2024, 62% of Canadian retail revenue, with pro forma 2024 capacity ~18,000 kg and SG&A gains improving gross margin ~4ppt; Dosecann ran 12,000 assays in 2025, keeping recalls <0.5% and supporting ~6% higher ASPs vs peers.

Auxly maintains dedicated consumer channels for product performance and quality inquiries, achieving median response times under 24 hours and resolving 82% of cases within 72 hours in 2025, which protects brand reputation and reduces churn. This direct feedback loop yields measurable insights—over 1,200 service tickets in 2025 drove three product iterations and a 7% improvement in customer-reported quality scores.

Auxly drives retention via social, email, SMS, app and in-person programs—2024 metrics: +22% repeat customers, +12% order frequency, +18% LTV vs one-offs, 46% 12‑month patient retention, 82% ticket resolution within 72h; community events and 1,200 retail trainings (8,500 staff) lifted shelf velocity +12%.

Provincial online stores and authorized private e-commerce sites let consumers buy Auxly products from home; in 2024 digital sales accounted for about 22% of Canadian cannabis retail revenue, up from 14% in 2021, boosting reach to remote areas. Auxly optimizes SEO, product images, and inventory feeds so items are easy to find online, reducing cart abandonment and supporting a growing share of tech-savvy customers.

Auxly sells via provincial wholesale portals (C$3.4B retail through distributors in 2024), retail stores (≈70% of sales; 60–75% of new-customer trials), online (22% of cannabis retail revenue in 2024), medical portals (medical gross margins up to 28%; ~42% repeat rate), and export (target EU/Israel; market growth 12–18% CAGR; +20–35% revenue uplift potential).

Wellness and medical patients use cannabis for targeted goals like sleep, pain, and anxiety relief; 2024 Canadian prescription-adjacent use rose 9% year-over-year, with 42% citing sleep as a primary reason. They demand lab-grade cannabinoid (THC/CBD) and terpene data for dosing and side-effect management, and choose products based on proven efficacy, safety records, and clinician recommendations—driving higher-margin, compliance-focused SKUs.

Core segments: Value-conscious (40–50% retail vol; ~35% Auxly SKU sales FY2025), Daily Convenience (54% concentrates/pre-pack purchases 2024; +18% basket value vs flower), Wellness/Medical (prescription-adjacent +9% YoY 2024; 42% cite sleep), Flavor Enthusiasts (+10–20% willingness to pay; 7% premium mix growth Q4 2024), New Users (38% want clear labels; 29% prefer ≤5 mg THC).

Marketing and brand development for Auxly requires significant spend—digital ads, retail displays, and marketing/sales salaries—typically 12–18% of revenue; Auxly reported C$16.4m SG&A on marketing-related lines in FY2024, underscoring this scale. These ongoing costs are essential to drive top-line growth in a crowded cannabis market where Nielsen found brand awareness lifts of 5–12% per major campaign in 2023.

Auxly’s dried flower and multi-pack pre-rolls still drive volume: in 2024 bulk flower and pre-roll sales accounted for ~42% of Auxly’s Canadian revenue, helping produce over 10,000 kg equivalent sold and supporting facility utilization above 78%, so they finance capacity and margins while 2.0 products scale.

Vape sales ~CAD45–55M (20–25% branded share FY2025), margins 55–65%, 6–8 units/yr; gummies/concentrates CAD42.5M in FY2024 (28% product revenue), margins ~42%; flower/pre-rolls ~42% of revenue, >10,000 kg eq sold, 78%+ utilization; medical CAD8.4M FY2024; licensing royalties 6–12%, gross margins >70%.